Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a daily probiotic soothe teen anxiety?

NCT ID NCT07752342

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study tests whether a daily probiotic supplement, Bifidobacterium longum 1714™, can improve wellbeing in adolescents aged 15-17 who report mild-to-moderate anxiety. Over 8 weeks, participants take one capsule daily and report changes in anxiety, sleep, fatigue, and cognitive function. The goal is to see if this probiotic, previously linked to stress and sleep benefits in adults, might help teens in everyday, real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bifidobacterium longum, 1714™ (a probiotic dietary supplement)
What this could lead to
If it works, this probiotic could offer a simple, non-drug way to help teens manage mild-to-moderate anxiety and improve sleep and wellbeing.
What could go wrong
This is an early, open-label study without a placebo, so results may be influenced by expectations. Effects seen in adults may not translate to adolescents, and the supplement may not outperform a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (Adolescents): * Aged 15-17 years at the time of study screening * Able and willing to provide informed consent or assent, with parental consent where applicable. * Enrolled in school or college at the time of screening * Participants must be able to read and understand English. * Self-reporting mild-to-moderate feelings of anxiety (≥55 and ≤69 T-score - mild-to-moderate anxiety - on PROMIS Pediatric Anxiety CAT, as assessed during screening * Owner of a personal smartphone which: (i) only they have access to, and (ii) has Apple AppStore or Android store access to the free-to-use Trialflare app. * Willing to: * Consume the study product daily for the duration of the study * Setup a Garmin account by email * Wear a provided wearable device during the study period * Complete study assessments digitally Exclusion Criteria (Adolescents): * Pregnant, breastfeeding, or planning pregnancy during the study period * Known allergy or intolerance to any component of the study product * Presence of a significant medical or psychiatric condition that may: * Pose a safety risk, or * Confound interpretation of study outcomes, as judged by the Investigator * Current diagnosis of: * Bipolar disorder * Clinical anxiety disorder or depression * Current or recent (within the last 3 months) use of: * Antidepressants, anxiolytics, or antibiotics * Other probiotic products * Supplements intended to affect mood, sleep, stress, or anxiety * N.B. Use of such items may still be considered via an adaptive approach, reducing the time to last use to 1 month instead of 3 months * Participation in another clinical or nutritional study that could interfere with this study * Current use of cognitive behavioural therapy or counselling to manage anxiety- or low mood-like symptoms * Considered by the PI to be a poor candidate for compliance or data submission Inclusion Criteria (Parents) * Legal guardian of an enrolled A-Participant * Living in the same household as the A-Participant * Able to provide informed consent * Owner of a personal smartphone compatible with the study application Exclusion Criteria (Parents) * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy young adults are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Comet Clinical

    Cardiff, United Kingdom

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.